{"id":53143,"date":"2023-01-20T16:02:57","date_gmt":"2023-01-20T15:02:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/"},"modified":"2023-01-20T16:02:57","modified_gmt":"2023-01-20T15:02:57","slug":"adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/","title":{"rendered":"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc.<\/a>, a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing to advance its drug development pipeline as the Company\u2019s first product enters the clinic. The Series B-1 was led by Ascenta Capital with the current syndicate of OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, and Sirona Capital all participating in the financing. In conjunction with this financing, Dr. Lorence Kim of Ascenta Capital has joined the Company\u2019s Board of Directors.\n<\/p>\n

<\/a><\/p>\n

\n\u201csiRNA has evolved from a spectacular platform technology into a new class of medicines. ADARx represents a next generation of unique insights into oligonucleotide chemistry, pushing siRNA\u2019s frontier with efficient translation of ADARx science into potential medicines addressing large unmet medical needs across therapeutic areas,\u201d said Dr. Lorence Kim of Ascenta Capital. \u201cMy co-founder, Evan Rachlin, and I formed Ascenta Capital to help companies like ADARx grow into and realize their potential. We are thrilled to partner with Dr. Li and her team as they move the portfolio into the first of many clinical studies of important new RNA medicines.\u201d\n<\/p>\n

\nThe proceeds from the Series B-1 financing will be used to advance ADARx\u2019s proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. The timing of this financing coincides with ADARx\u2019s lead product candidate, ADX-324, for the treatment of hereditary angioedema beginning its phase I clinical trial.\n<\/p>\n

\n\u201cThis is an exciting time for ADARx as we make the transition to a clinical stage biotechnology company,\u201d said Dr. Zhen Li, President, and Chief Executive Officer of ADARx. \u201cThis round of funding with the support of our investor syndicate allows us to pursue our near-term objectives of progressing our first three product candidates into the clinic while continuing our discovery and development efforts across multiple therapeutic areas.\u201d\n<\/p>\n

\nAbout ADARx<\/b>\n<\/p>\n

\nADARx Pharmaceuticals, Inc.<\/a>, located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.\n<\/p>\n

\nAbout Ascenta Capital<\/b>\n<\/p>\n

\nAscenta Capital is a biotech-focused late-stage venture fund, co-founded in 2023 by Dr. Evan Rachlin and Dr. Lorence Kim. The fund is focused on concentrated investments in companies developing portfolios of therapeutics based on innovative platform technologies. For more information about Ascenta Capital, visit www.ascentacap.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nADARx Contact<\/b>
Roselle Corbaley
\n
(877) 232-7974
\n
ir@adarx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing to advance its drug development pipeline as the Company\u2019s first product enters the clinic. The Series B-1 was led by Ascenta Capital with the current syndicate of OrbiMed Advisors, SR One … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53143","6":"format-standard","7":"category-industry"},"yoast_head":"\nADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing to advance its drug development pipeline as the Company\u2019s first product enters the clinic. The Series B-1 was led by Ascenta Capital with the current syndicate of OrbiMed Advisors, SR One ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-20T15:02:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230120005072\/en\/1691371\/21\/ADARX-Logo-Color-Horizontal.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic\",\"datePublished\":\"2023-01-20T15:02:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/\"},\"wordCount\":453,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005072\\\/en\\\/1691371\\\/21\\\/ADARX-Logo-Color-Horizontal.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/\",\"name\":\"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005072\\\/en\\\/1691371\\\/21\\\/ADARX-Logo-Color-Horizontal.jpg\",\"datePublished\":\"2023-01-20T15:02:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005072\\\/en\\\/1691371\\\/21\\\/ADARX-Logo-Color-Horizontal.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230120005072\\\/en\\\/1691371\\\/21\\\/ADARX-Logo-Color-Horizontal.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/","og_locale":"en_US","og_type":"article","og_title":"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the close of a $46 million Series B-1 financing to advance its drug development pipeline as the Company\u2019s first product enters the clinic. The Series B-1 was led by Ascenta Capital with the current syndicate of OrbiMed Advisors, SR One ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-20T15:02:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230120005072\/en\/1691371\/21\/ADARX-Logo-Color-Horizontal.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic","datePublished":"2023-01-20T15:02:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/"},"wordCount":453,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230120005072\/en\/1691371\/21\/ADARX-Logo-Color-Horizontal.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/","url":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/","name":"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230120005072\/en\/1691371\/21\/ADARX-Logo-Color-Horizontal.jpg","datePublished":"2023-01-20T15:02:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230120005072\/en\/1691371\/21\/ADARX-Logo-Color-Horizontal.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230120005072\/en\/1691371\/21\/ADARX-Logo-Color-Horizontal.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/adarx-pharmaceuticals-raises-46-million-as-lead-product-enters-the-clinic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53143"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53143\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}